Autoimmune Disease Diagnostics Market Size & Share 2026-2035
Download Free PDF
Report Content
Chapter 1. Research Methodology
1.1 Research Approach
1.2 Quality Commitments
1.2.1 GMI AI Policy & Data Integrity Commitment
1.2.1.1 Source Consistency Protocol
1.3 Research Trail & Confidence Scoring
1.3.1 Research Trail Components
1.3.2 Scoring Components
1.4 Data Collection
1.4.1 Partial List of Primary Sources
1.5 Data Mining Sources
1.5.1 Paid Sources
1.5.1.1 Sources, by Region
1.6 Base Estimates & Calculations
1.6.1 Base Year Calculation
1.7 Forecast Model
1.7.1 Quantified Market Impact Analysis
1.7.1.1 Mathematical Impact of Growth Parameters on Forecast
1.8 Research Transparency Addendum
1.8.1 Source Attribution Framework
1.8.2 Quality Assurance Metrics
1.8.3 Our Commitment to Trust
Chapter 2. Executive Summary
2.1 Industry 360° Synopsis
2.2 Key Market Trends
2.2.1 Product Trends (Chapter 5 — By Product)
2.2.2 Disease Type Trends (Chapter 6 — By Disease Type)
2.2.3 Test Type Trends (Chapter 7 — By Test Type)
2.2.4 End-Use Trends (Chapter 8 — By End Use)
2.2.5 Regional Trends (Chapter 9 — By Region)
2.3 TAM Analysis, 2027–2035
2.4 CXO Perspectives: Strategic Imperatives
Chapter 3. Industry Insights
3.1 Industry Ecosystem Analysis
3.1.1 Supplier Landscape
3.1.2 Profit Margin
3.1.3 Cost Structure
3.1.4 Value Addition at Each Stage
3.1.5 Factors Affecting the Value Chain
3.1.6 Disruptions
3.2 Industry Impact Forces
3.2.1 Growth Drivers
3.2.1.1 Rising Global Prevalence of Autoimmune Diseases (RA, SLE, MS, T1D, IBD) Driving Diagnostic Testing Volumes
3.2.1.2 Growing Demand for Early & Accurate Autoimmune Diagnosis Across Hospital & Reference Lab Settings
3.2.1.3 Technological Advancements in High-Throughput Immunoassay & Multiplex Autoantibody Testing Platforms
3.2.1.4 Expanding Healthcare Infrastructure & Diagnostic Lab Capacity in Emerging Markets
3.2.1.5 Increasing Clinician & Patient Awareness of Autoimmune Conditions Accelerating Testing Adoption
3.2.2 Industry Pitfalls & Challenges
3.2.2.1 High Cost of Advanced Immunoassay Analyzers Limiting Adoption in Low-Income & Resource-Constrained Settings
3.2.2.2 Diagnostic Complexity Due to Overlapping Autoimmune Biomarkers & Non-Specific Clinical Presentations
3.2.2.3 Reimbursement Gaps & Insurance Coverage Limitations for Specialized Autoimmune Testing Panels
3.2.2.4 Shortage of Skilled Laboratory Personnel for Specialized Immunology & Autoimmune Testing Workflows
3.2.2.5 Stringent IVD Regulatory Approval Pathways Increasing Time-to-Market for New Autoimmune Assays
3.2.3 Market Opportunities
3.2.3.1 AI & Machine Learning Integration for Pattern Recognition in Autoimmune Biomarker Interpretation & Early Diagnosis
3.2.3.2 Development of Multiplex Autoantibody Panels Reducing Time-to-Diagnosis & Improving Clinical Accuracy
3.2.3.3 Decentralized & Near-Patient Autoimmune Testing Creating New Revenue Streams Beyond Central Laboratory
3.2.3.4 Emerging Market Expansion Driven by Rising Healthcare Expenditure & Growing Autoimmune Disease Awareness
3.2.3.5 Liquid Biopsy & Next-Generation Sequencing Applications Opening New Frontiers in Autoimmune Diagnostics
3.3 Growth Potential Analysis
3.4 Pricing Analysis (Driven by Primary Research)
3.4.1 Historical Price Trend Analysis (Driven by Primary Research)
3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus) (Driven by Primary Research)
3.5 Regulatory Landscape
3.5.1 North America
3.5.2 Europe
3.5.3 Asia Pacific
3.5.4 Latin America
3.5.5 Middle East & Africa
3.6 Porter's Analysis
3.7 PESTEL Analysis
3.8 Trade Data Analysis (Based on Paid Database)
3.8.1 Import/Export Volume & Value Trends (Based on Paid Database)
3.8.2 Key Trade Corridors & Tariff Impact (Based on Paid Database)
3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
3.9.1 AI-Driven Disruption of Existing Business Models
3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
3.9.3 Risks, Limitations & Regulatory Considerations
Chapter 4. Competitive Landscape, 2025
4.1 Introduction
4.2 Company Market Share Analysis
4.2.1 By Region
4.2.1.1 North America
4.2.1.2 Europe
4.2.1.3 Asia Pacific
4.2.1.4 Latin America
4.2.1.5 Middle East & Africa
4.2.2 Market Concentration Analysis
4.3 Competitive Analysis of Major Market Players
4.4 Competitive Positioning Matrix
4.5 Key Developments
4.5.1 Mergers & Acquisitions
4.5.2 Partnerships & Collaborations
4.5.3 New Product Launches
4.5.4 Expansion Plans & Funding
4.6 Company Tier Benchmarking
4.6.1 Tier Classification Criteria & Qualifying Thresholds
4.6.2 Tier Positioning Matrix by Revenue, Geography & Innovation
Chapter 5. Autoimmune Disease Diagnostics Market Estimates & Forecast, By Product (USD Million, 2022–2035)
5.1 Reagents & Consumables
5.2 Instruments
Chapter 6. Autoimmune Disease Diagnostics Market Estimates & Forecast, By Disease Type (USD Million, 2022–2035)
6.1 Localized Autoimmune
6.1.1 Type 1 Diabetes (T1D)
6.1.2 Inflammatory Bowel Disease (IBD)
6.1.3 Thyroid Autoimmune Disorders
6.1.4 Others (Localized)
6.2 Systemic Autoimmune
6.2.1 Rheumatoid Arthritis (RA)
6.2.2 Systemic Lupus Erythematosus (SLE)
6.2.3 Multiple Sclerosis (MS)
6.2.4 Psoriasis
6.2.5 Others (Systemic)
Chapter 7. Autoimmune Disease Diagnostics Market Estimates & Forecast, By Test Type (USD Million, 2022–2035)
7.1 ANA (Antinuclear Antibody) Tests
7.2 Autoantibody Tests (anti-CCP, anti-dsDNA, RF, etc.)
7.3 Complete Blood Count (CBC)
7.4 CRP & Inflammatory Markers
7.5 Urinalysis
7.6 Others
Chapter 8. Autoimmune Disease Diagnostics Market Estimates & Forecast, By End Use (USD Million, 2022–2035)
8.1 Hospitals
8.2 Diagnostic Centers / Reference Labs
8.3 Others (Clinics, Academic & Research Institutes)
Chapter 9. Autoimmune Disease Diagnostics Market Estimates & Forecast, By Region (USD Million, 2022–2035)
9.1 North America
9.1.1 U.S.
9.1.1.1 By Product
9.1.1.2 By Disease Type
9.1.1.3 By Test Type
9.1.1.4 By End Use
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 UK
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Netherlands
9.2.7 Rest of Europe
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 South Korea
9.3.5 Australia
9.3.6 Rest of Asia Pacific
9.4 Latin America
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Argentina
9.4.4 Rest of Latin America
9.5 Middle East & Africa
9.5.1 Saudi Arabia
9.5.2 UAE
9.5.3 South Africa
9.5.4 Rest of Middle East & Africa
Chapter 10. Company Profiles (Driven by Primary Research)
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at [email protected]
Share Content
Add Citations
Monali Tayade. 2026, November. Autoimmune Disease Diagnostics Market (Report ID: GMI618). Global Market Insights Inc. Retrieved November 13, 2026, from https://www.gminsights.com/toc/details/autoimmune-disease-diagnostics-market
Autoimmune Disease Diagnostics Market
Get a free sample of this report
Autoimmune Disease Diagnostics Market Size
The autoimmune disease diagnostics market was valued at USD 6.20 billion in 2025, advances to USD 6.73 billion in 2026, is projected to grow at a 6.9% CAGR (2026–2035), and is forecast to reach USD 12.12 billion by 2035. The market is underpinned by the recurring nature of autoimmune care: initial characterization is followed by years of disease-activity assessment, treatment monitoring, and flare-related testing. Demand therefore favors laboratory workflows that combine broad autoantibody coverage with reliable replenishment of disease-specific reagents.
GMI Analyst View
Our cross-market benchmarking of the in vitro diagnostics sector shows that the global IVD market reached USD 108.6 billion in 2025. We view autoimmune diagnostics as a comparatively durable specialty within this landscape because chronic, multi-organ conditions require longitudinal laboratory engagement rather than a single diagnostic encounter. Platforms that improve diagnostic yield while fitting established laboratory workflows should be best placed to turn that continuity into recurring revenue.
Autoimmune Disease Diagnostics Market Trends, Growth Drivers & GMI Forecast Outlook
The market's trajectory reflects expanding chronic-disease monitoring, increasing use of multiplex autoantibody workflows, and continued investment in automated testing capacity. Adoption is moderated by delayed diagnosis, variable reimbursement for comprehensive panels, and regulatory transitions that can defer laboratory purchasing decisions.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
A growing systemic autoimmune caseload expands the installed base of patients requiring periodic autoantibody and inflammatory-marker testing. This is commercially significant because monitoring protocols link the initial diagnostic workup to repeat laboratory utilization, supporting resilient reagent demand even when hospitals defer larger capital purchases.
The U.S. diagnosed population supports dense referral flows through hospital systems and specialty laboratories. At high volumes, laboratory operators have stronger incentives to consolidate sequential single-marker requests into validated panel workflows, improving throughput while preserving clinical specificity for rheumatology and immunology services.
Multiplex systems can shorten the path from screening to disease characterization by producing a broader clinical picture from one sample [3]AliveDx. "AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray." prnewswire.co.uk. Their adoption raises the strategic value of menu breadth, automation, and assay validation, while favoring suppliers with reagent portfolios that can support repeated monitoring after the initial diagnostic episode.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Long diagnostic journeys leave part of the potential monitoring population outside structured autoimmune testing pathways. Specialist shortages, referral friction, and uneven access to confirmatory testing can delay transition from nonspecific symptoms to a repeat-testing regimen, especially in systems where primary care has limited access to rheumatology expertise.
Misdiagnosis also weakens the efficiency of laboratory spending by directing testing toward broad or poorly matched workups rather than targeted disease characterization [5]Review authors. "Understanding the impact of delayed diagnosis and misdiagnosis of systemic lupus erythematosus (SLE)." pmc.ncbi.nlm.nih.gov. The clinical case for broader panels is clear, but their commercial uptake remains dependent on reimbursement models that recognize the value of resolving uncertainty earlier in the care pathway.
Method differences between ANA screening technologies add another layer of friction. Laboratories must manage comparability, validation, and regulatory compliance before changing platforms, which can slow instrument placements and assay-menu transitions even where the underlying clinical demand remains intact.
GMI Analyst View
We believe the market is moving from assay-led ordering toward workflow-led purchasing. The suppliers best positioned for this transition are those that can demonstrate clinical utility across the diagnostic pathway, rather than merely add another isolated marker to a laboratory menu. Reimbursement remains the principal pacing factor: clinical demand can emerge before payment systems fully recognize the operational value of comprehensive panels.
Autoimmune Disease Diagnostics Market Segment Analysis
By Product
Reagents & Consumables
Reagents and consumables generated USD 4.46 billion in 2025 and are projected to account for a 74.0% share in 2035. In the autoimmune disease diagnostics market, each screening, confirmatory, or monitoring episode draws on replenishable assay inputs, creating a direct link between patient testing cadence and recurring supplier revenue. Broader panel configurations should further reinforce consumable intensity at established laboratory sites.
Instruments
Instruments are projected to generate USD 3.15 billion in 2035 and represented a 28.0% share in 2025. Demand is tied to laboratory automation, replacement cycles, and new facility buildouts, making the segment more exposed to capital-budget timing than consumables. Suppliers that pair analyzers with validated specialty menus can strengthen placement economics and build longer-term reagent pull-through.
By Disease Type
Systemic Autoimmune
Systemic autoimmune testing represented a 65.0% share in 2025 and is projected to reach USD 8.24 billion by 2035. Multi-organ disease presentation often requires a combination of screening, confirmatory, and activity-monitoring assays, making systemic conditions particularly attractive for laboratories with broad autoantibody menus. This complexity supports higher testing intensity per patient episode than narrower organ-specific workflows.
Localized Autoimmune
Localized autoimmune testing generated USD 2.17 billion in 2025 and is expected to hold a 32.0% share in 2035. Thyroid disorders, type 1 diabetes, and gastrointestinal conditions sustain substantial volume through well-defined testing pathways, although they generally require fewer concurrent panels than systemic disorders. Their commercial importance rests on population scale, standardization, and integration into routine chronic-care management.
Rheumatoid Arthritis (RA)
Rheumatoid arthritis diagnostics generated USD 1.12 billion in 2025 and are projected to account for a 19.0% share in 2035. Anti-CCP and rheumatoid factor testing anchor both early assessment and longitudinal disease management, giving the category a dependable repeat-testing profile. The expanding global RA burden supports a larger pool of patients entering these serial laboratory pathways [1]GBD 2021 Rheumatoid Arthritis Collaborators. "Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050." thelancet.com.
Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus diagnostics represented an 11.0% share in 2025 and are forecast to generate USD 1.39 billion by 2035. Lupus requires clinicians to reconcile heterogeneous symptoms with changing organ involvement, which favors repeated combinations of ANA, anti-dsDNA, complement, and renal monitoring. The opportunity is tempered by diagnostic uncertainty, but that same complexity increases the value of well-integrated panel strategies.
Multiple Sclerosis (MS)
Multiple sclerosis diagnostics generated USD 523 million in 2025 and are projected to grow at a 7.6% CAGR (2026–2035). The category is benefiting from a broader monitoring toolkit that complements established cerebrospinal fluid testing with more accessible biomarker approaches. These methods can expand follow-up testing while reducing reliance on invasive procedures for certain monitoring decisions.
Psoriasis
Psoriasis diagnostics represented a 7.1% share in 2025 and are forecast to generate USD 848 million by 2035. Laboratory testing is becoming more relevant as providers distinguish inflammatory psoriasis from related arthritic conditions and monitor patients receiving biologic therapies. This shifts the category beyond a purely clinical dermatology diagnosis toward a more sustained laboratory-supported management model.
Type 1 Diabetes (T1D)
Type 1 diabetes diagnostics generated USD 607 million in 2025 and are projected to represent a 9.0% share in 2035. Islet autoantibody testing supports diagnostic confirmation and risk assessment, while screening initiatives can widen testing beyond symptomatic populations. The segment benefits from a care model in which early identification has clinical and monitoring implications across pediatric and specialist settings.
Thyroid Autoimmune Disorders
Thyroid autoimmune disorder diagnostics represented an 11.2% share in 2025 and are forecast to generate USD 1.24 billion by 2035. Anti-TPO and anti-TG testing is embedded in well-recognized care pathways for Hashimoto's thyroiditis and Graves' disease, enabling broad clinical adoption. Its relative accessibility makes the category an important volume contributor in markets with less developed specialty laboratory infrastructure.
Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease diagnostics generated USD 391 million in 2025 and are projected to reach USD 703 million by 2035. Testing supports differentiation of inflammatory disease from functional gastrointestinal conditions and helps monitor response to therapy. Demand is reinforced where laboratory markers can reduce dependence on invasive procedures or improve the timing of specialist referral.
By Test Type
ANA (Antinuclear Antibody) Tests
ANA tests generated USD 1.36 billion in 2025 and are projected to account for a 21.0% share in 2035. ANA remains an essential entry point for suspected systemic autoimmune disease, ensuring durable testing volumes. However, its role as a screening tool also creates demand for follow-on assays that establish antibody specificity and clinical relevance.
Autoantibody Tests
Autoantibody tests represented a 28.0% share in 2025 and are forecast to generate USD 3.63 billion by 2035. The category is favored by the shift from broad screening toward disease-specific characterization, particularly where therapy selection and monitoring require higher diagnostic confidence. Menu depth and assay performance are therefore key competitive variables for suppliers serving specialist laboratories.
Complete Blood Count (CBC)
Complete blood count testing generated USD 1.11 billion in 2025 and is projected to hold a 16.0% share in 2035. CBC remains a routine component of autoimmune monitoring because hematologic abnormalities can signal disease activity or treatment effects. Its value lies in integration with more specific testing rather than differentiation as a stand-alone autoimmune assay.
CRP & Inflammatory Markers
CRP and inflammatory markers represented a 14.0% share in 2025 and are projected to grow at a 6.1% CAGR (2026–2035). These markers are used across multiple autoimmune conditions to assess inflammatory activity and treatment response. Their broad clinical applicability provides stable volume, while increasingly targeted biologic therapies create additional demand for longitudinal monitoring.
Urinalysis
Urinalysis generated USD 496 million in 2025 and is forecast to reach USD 970 million by 2035. The test is integral to detecting renal involvement in lupus and other systemic conditions, supporting regular use in chronic monitoring protocols. Its recurring role in renal surveillance makes the category a dependable complement to autoantibody testing.
Others
Other test types represented a 10.0% share in 2025 and are projected to grow at an 8.9% CAGR (2026–2035). Flow cytometry, cytokine profiling, complement testing, and other advanced methods are expanding the clinical information available to specialists. Their growth reflects a gradual migration of advanced immune characterization from tertiary settings into broader laboratory practice.
By End Use
Hospitals
Hospitals generated USD 2.79 billion in 2025 and are projected to account for a 43.0% share in 2035. They remain the central setting for initial workups, acute flares, and clinically complex cases requiring coordinated specialist input. Their testing demand favors comprehensive platforms that can support both emergency and scheduled autoimmune workflows.
Diagnostic Centers / Reference Labs
Diagnostic centers and reference laboratories represented a 38.0% share in 2025 and are forecast to generate USD 4.90 billion by 2035. Their high-throughput operating model supports investment in automation, specialty validation, and broad menus that smaller laboratories may not maintain economically. As stable patients shift toward outpatient management, centralized reference services should capture a larger share of routine monitoring.
Others
Other end users generated USD 1.05 billion in 2025 and are projected to grow at a 6.6% CAGR (2026–2035). Specialty clinics, academic medical centers, and research institutions often adopt emerging biomarker approaches before they diffuse into high-volume clinical settings. This channel therefore serves as an important early indicator of future assay-menu expansion.
GMI Analyst View
We see the segment structure as a contest between diagnostic complexity and operational simplicity. The highest-value clinical questions often arise in diseases where certainty is hardest to achieve, creating room for validated multiplex solutions but also raising the evidence threshold for adoption. Competitive advantage will depend on making broader testing clinically actionable without creating cost or workflow burdens that laboratories cannot absorb.
Autoimmune Disease Diagnostics Market Regional Analysis
North America Autoimmune Disease Diagnostics Market Analysis
North America generated USD 2.54 billion in 2025 and is projected to hold a 37.6% share in 2035. The autoimmune disease diagnostics market in North America benefits from mature reference-laboratory networks, extensive hospital automation, and established specialist referral pathways. These conditions support high-volume testing across initial screening, confirmatory analysis, and chronic disease monitoring.
U.S.
The U.S. represented a 37.0% share in 2025 and is projected to generate USD 4.10 billion by 2035. Large reference laboratories and integrated hospital systems create a favorable environment for scaled autoimmune testing, particularly in outpatient specialist workflows. Continued menu expansion and digital ordering infrastructure should sustain demand for comprehensive diagnostic services.
Canada
Canada generated USD 249 million in 2025 and is projected to grow at a 6.3% CAGR (2026–2035). Centralized provincial laboratory systems provide efficiency in urban markets, while geographic dispersion can restrict access in remote communities. Telehealth-enabled referrals and expanded specialist networks are likely to improve the reach of autoimmune testing over time.
Europe Autoimmune Disease Diagnostics Market Analysis
Europe represented a 27.0% share in 2025 and is forecast to grow at a 5.8% CAGR (2026–2035). Mature clinical protocols sustain demand for specialty assays, but the region faces near-term complexity from EU IVDR compliance and fragmented procurement environments. Suppliers with robust regulatory support and established laboratory relationships are better positioned to navigate these transitions.
Germany
Germany generated USD 368 million in 2025 and is projected to account for a 5.2% share in 2035. High laboratory automation and a strong rheumatology infrastructure support consistent utilization of ANA and disease-specific autoantibody tests. The country also remains strategically important for specialist assay suppliers with established immunology capabilities.
UK
The UK represented a 4.9% share in 2025 and is projected to grow at a 5.8% CAGR (2026–2035). Centralized commissioning concentrates testing volume in specialist centers, supporting automation and standardization. Growth will depend on how effectively primary care pathways identify and refer patients requiring more comprehensive autoimmune assessment.
France
France generated USD 268 million in 2025 and is projected to account for a 3.8% share in 2035. University hospitals and public laboratory networks remain important sites for comprehensive autoimmune workups and biomarker adoption. The country's academic immunology base supports early evaluation of new assays, although reimbursement and hospital procurement shape the pace of broader diffusion.
Italy
Italy generated USD 218 million in 2025 and is projected to hold a 3.0% share in 2035. Regional differences in laboratory capability create uneven adoption, with more developed northern networks leading the use of comprehensive panels. Greater awareness in primary care can increase referral volumes, but scalable access depends on regional health-system investment.
Spain
Spain represented a 3.0% share in 2025 and is projected to grow at a 5.3% CAGR (2026–2035). Regional health authorities play a central role in laboratory procurement, making platform standardization uneven across the country. Expanding outpatient rheumatology capacity and automation should gradually increase testing intensity.
Netherlands
The Netherlands generated USD 117 million in 2025 and is forecast to reach USD 196 million by 2035. Integrated hospital networks and high automation density support efficient platform utilization. Its tertiary centers are well placed to adopt specialized panel technologies where clinical evidence and laboratory workflow improvements are clear.
Asia Pacific Autoimmune Disease Diagnostics Market Analysis
Asia Pacific generated USD 1.42 billion in 2025 and is projected to represent a 28.5% share in 2035. The autoimmune disease diagnostics market in Asia Pacific is expanding as hospital laboratory capacity, specialist awareness, and healthcare spending rise across markets with widely different maturity levels. Growth is supported by both high-volume infrastructure investment and the formalization of diagnostic pathways in previously underserved populations.
China
China represented an 8.7% share in 2025 and is projected to generate USD 1.34 billion by 2035. Investment in hospital standards and laboratory modernization is expanding access to autoimmune testing beyond major tertiary centers. The market combines large potential testing volumes with price-sensitive competition from domestic and multinational IVD suppliers.
Japan
Japan generated USD 328 million in 2025 and is forecast to grow at a 6.2% CAGR (2026–2035). High baseline automation and established rheumatology practice support steady demand from an already developed diagnostic base. Population aging reinforces the need for ongoing monitoring of chronic autoimmune conditions.
India
India represented a 3.7% share in 2025 and is projected to grow at an 11.5% CAGR (2026–2035). Private hospital expansion and rising specialist awareness are increasing use of autoimmune testing in major urban centers. The opportunity is centered on extending access from basic screening to more specific autoantibody panels as laboratory capabilities mature.
South Korea
South Korea generated USD 171 million in 2025 and is projected to account for a 3.2% share in 2035. Universal coverage, advanced clinical specialization, and a strong domestic IVD industry support both standard and premium assay demand. Competition is likely to remain focused on balancing platform performance with cost efficiency.
Australia
Australia represented a 1.6% share in 2025 and is forecast to generate USD 181 million by 2035. Centralized pathology providers and automated platforms support high test throughput, while remote care models can extend specialist access beyond metropolitan centers. The market remains mature but benefits from structured referral and reimbursement pathways.
Latin America Autoimmune Disease Diagnostics Market Analysis
Latin America generated USD 341 million in 2025 and is projected to grow at a 7.0% CAGR (2026–2035). Growth is supported by specialist awareness, private laboratory investment, and expanding hospital capacity, although reimbursement for complex panels remains uneven. Brazil and Mexico provide the principal scale, while other markets are influenced more heavily by local economic conditions and import dependence.
Brazil
Brazil represented a 2.5% share in 2025 and is projected to grow at a 7.0% CAGR (2026–2035). Public laboratory expansion and private diagnostic networks are increasing autoimmune testing capacity in major urban areas. The country's population scale creates significant upside as specialty referral pathways become more established.
Mexico
Mexico generated USD 95 million in 2025 and is forecast to grow at a 7.1% CAGR (2026–2035). Specialty testing remains concentrated in large metropolitan areas and private hospital networks. Continued growth depends on broadening clinician awareness and improving affordability for patients seeking advanced diagnostic services.
Argentina
Argentina represented a 0.9% share in 2025 and is projected to generate USD 114 million by 2035. Strong clinical expertise and academic rheumatology capacity support underlying demand, but macroeconomic volatility can constrain equipment investment and reagent supply continuity. Market progress will depend on the stability of healthcare purchasing conditions.
Middle East & Africa Autoimmune Disease Diagnostics Market Analysis
Middle East & Africa represented a 3.5% share in 2025 and is projected to generate USD 533 million by 2035. Growth is concentrated in Gulf markets investing in specialty laboratory capability, while much of Africa remains limited by specialist availability and diagnostic infrastructure. The result is a region with strong premium demand pockets alongside substantial unmet need.
Saudi Arabia
Saudi Arabia represented a 1.05% share in 2025 and is forecast to generate USD 160 million by 2035. Investment in hospital laboratory capacity and specialist services supports broader access to autoimmune testing. Procurement increasingly favors platforms that combine international quality standards with the ability to support complex referral-center workflows.
UAE
The UAE generated USD 54 million in 2025 and is projected to grow at a 9.4% CAGR (2026–2035). Dubai and Abu Dhabi's role as healthcare hubs supports demand for sophisticated laboratory automation and internationally accredited testing services. A sizable private-care segment provides a receptive setting for premium specialty assays.
South Africa
South Africa represented a 0.70% share in 2025 and is forecast to generate USD 106 million by 2035. Private laboratories provide the most developed specialty testing infrastructure on the continent, while public-sector capacity remains more limited. Expanding referral pathways can increase access, but affordability and workforce availability remain material constraints.
GMI Analyst View
We expect regional expansion to reward differentiated go-to-market models rather than a uniform global strategy. High-throughput demand in China, specialist-led market creation in India, and premium procurement criteria in Gulf countries call for different combinations of menu depth, service support, pricing, and regulatory execution. Suppliers that localize these choices should be better positioned to capture the next phase of geographic growth.
Autoimmune Disease Diagnostics Market Share & Competitive Landscape
The autoimmune disease diagnostics market share structure is moderately concentrated, with global platform manufacturers and major reference laboratories holding leading positions while specialist assay providers retain meaningful roles in focused testing categories. Roche Diagnostics held a 13.3% share in 2025, supported by its broad automated immunoassay presence and established relationships with hospital and reference-laboratory customers.
Quest Diagnostics held an 11.9% share in 2025. Its position reflects the strategic importance of the U.S. reference-laboratory channel, where integrated ordering, broad specialty menus, and scalable sample processing can reinforce long-term physician referral relationships.
Siemens Healthineers held a 10.8% share in 2025. The company's competitive position is strengthened by its ability to participate in broader health-system capital decisions, linking laboratory automation with a wider diagnostics portfolio and service infrastructure.
Labcorp held a 10.5% share in 2025. Its centralized specialty testing model supports high-throughput assay validation and workflow standardization, enabling it to compete for outpatient monitoring demand as chronic autoimmune care shifts away from inpatient settings.
Thermo Fisher Scientific held a 9.5% share in 2025. Its autoimmune diagnostics position benefits from specialty assay capabilities and proximity to emerging biomarker science, which can support the translation of research tools into clinically validated test offerings.
Competition also includes Abbott, bioMérieux, Bio-Rad, DIAsource, Euroimmun, GRIFOLS, Hemagen Diagnostics, Inova Diagnostics (Werfen), Revvity, and Trinity Biotech. The market's competitive intensity is shaped by assay-menu breadth, analytical validation, service capability, installed-base economics, regulatory execution, and the ability to support laboratories as they move from individual marker testing toward broader diagnostic panels.
Recent Industry Developments
AliveDx submitted a U.S. FDA 510(k) application in April 2025 for its MosaiQ AiPlex® CTDplus multiplex microarray, extending the industry's shift toward consolidated connective-tissue-disease characterization from a single patient sample [3]AliveDx. "AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray." prnewswire.co.uk. The development illustrates how assay developers are seeking to reduce sequential ordering and improve the operational fit of complex autoimmune testing.
bioMérieux announced an agreement in January 2025 to acquire SpinChip Diagnostics, adding near-patient immunoassay capabilities to its diagnostic portfolio [6]bioMérieux. "bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip." biomerieux.com. Although the platform's early applications target other clinical areas, the transaction signals continued interest in bringing sensitive immunoassay workflows closer to the point of care.
VolitionRx announced a research license and exclusive commercial option rights agreement with Werfen in September 2025 to investigate its Nu.Q® H3.1 NETs assay for antiphospholipid syndrome diagnostics [7]VolitionRx Limited. "Volition signs first human out-licensing deal." volition.com. The agreement highlights ongoing interest in novel biomarker approaches for autoimmune conditions where existing diagnostic pathways can leave clinically important uncertainty unresolved.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.